LanzaTech (LNZA) said Tuesday it plans to spin out its synthetic biology unit LanzaX through a partnership with Tharsis Capital to prioritize its primary biorefining operations.
The spin-out will transfer more than 30 employees and existing contracts to LanzaX, aiming to reduce LanzaTech's annual costs by $8 million, the company said.
Timing of the move was described as "in the coming months."
LanzaTech added Tharsis Capital will support LanzaX in securing investments for its pipeline, which includes biochemicals and specialty products.
The company said it appointed Justin Pugh as interim CFO, succeeding Geoff Trukenbrod, effective immediately, who previously worked for FTI Capital Advisors in the same capacity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.